FRANKFURT (dpa-AFX Broker) - Carl Zeiss Med itec shares suffered on Friday from a negative study by the investment bank Stifel Europe. They lost 2.8 percent to 79.98 euros shortly after the start of trading. Analyst Dylan Van Haaften re-included the shares of the MDax medical technology company in the rating with a "sell" and a price target of 74 euros.

The main reason for his pessimistic stance is China. In particular, he pointed to the destocking of consumables for refractive surgery, price reductions in the government's volume-based procurement (VBP) and a higher basis for operating costs.

Van Haaften's estimates for the operating result (EBIT) for 2024 and 2025 are significantly below consensus./ck/mis